DK0956861T3 - Kombinationsterapi omfattende ribavirin og interferon-alfa til patienter med kronisk hepatitis C infektion, der ikke har modtaget antiviral behandling - Google Patents

Kombinationsterapi omfattende ribavirin og interferon-alfa til patienter med kronisk hepatitis C infektion, der ikke har modtaget antiviral behandling

Info

Publication number
DK0956861T3
DK0956861T3 DK99303729T DK99303729T DK0956861T3 DK 0956861 T3 DK0956861 T3 DK 0956861T3 DK 99303729 T DK99303729 T DK 99303729T DK 99303729 T DK99303729 T DK 99303729T DK 0956861 T3 DK0956861 T3 DK 0956861T3
Authority
DK
Denmark
Prior art keywords
interferon
infection
patients
alpha
chronic hepatitis
Prior art date
Application number
DK99303729T
Other languages
Danish (da)
English (en)
Inventor
Janice K Albrecht
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22151354&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0956861(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of DK0956861T3 publication Critical patent/DK0956861T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
DK99303729T 1998-05-15 1999-05-13 Kombinationsterapi omfattende ribavirin og interferon-alfa til patienter med kronisk hepatitis C infektion, der ikke har modtaget antiviral behandling DK0956861T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7956698A 1998-05-15 1998-05-15

Publications (1)

Publication Number Publication Date
DK0956861T3 true DK0956861T3 (da) 2002-07-01

Family

ID=22151354

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99303729T DK0956861T3 (da) 1998-05-15 1999-05-13 Kombinationsterapi omfattende ribavirin og interferon-alfa til patienter med kronisk hepatitis C infektion, der ikke har modtaget antiviral behandling

Country Status (23)

Country Link
EP (3) EP0956861B1 (pt)
JP (2) JP5281726B2 (pt)
KR (1) KR100694345B1 (pt)
CN (1) CN1230198C (pt)
AR (1) AR019551A1 (pt)
AT (1) ATE216591T1 (pt)
AU (2) AU766597B2 (pt)
BR (1) BR9910505A (pt)
CA (1) CA2331823A1 (pt)
CZ (1) CZ300540B6 (pt)
DE (1) DE69901321T2 (pt)
DK (1) DK0956861T3 (pt)
ES (1) ES2172288T3 (pt)
HK (1) HK1021131A1 (pt)
HU (1) HU230432B1 (pt)
IL (3) IL139220A0 (pt)
MY (1) MY129244A (pt)
NO (1) NO330715B1 (pt)
NZ (1) NZ507621A (pt)
PT (1) PT956861E (pt)
SK (1) SK288038B6 (pt)
TW (1) TWI277424B (pt)
WO (1) WO1999059621A1 (pt)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR021876A1 (es) * 1998-12-18 2002-08-07 Schering Corp Terapia de combinacion para vhc por induccion de ribavirina - interferon alfa pegilado
BR0016162A (pt) * 1999-12-23 2002-08-13 Ribapharm Composições e métodos para l-nucleosìdeos, lnucleotìdeos e seus análogos
JP4536194B2 (ja) * 2000-02-17 2010-09-01 大日本住友製薬株式会社 安定な注射用製剤
US6926898B2 (en) 2000-04-12 2005-08-09 Human Genome Sciences, Inc. Albumin fusion proteins
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
JP5230052B2 (ja) 2000-05-26 2013-07-10 イデニクス（ケイマン）リミテツド フラビウイルスおよびペスチウイルス治療のための方法および組成物
EP1326594A2 (en) * 2000-10-18 2003-07-16 Schering Corporation Ribavirin-pegylated interferon alfa hcv combination therapy
CN100438870C (zh) * 2001-11-09 2008-12-03 精达制药公司 ω干扰素在制备治疗温血动物对象中病毒性疾病的药物中的用途
ES2500918T3 (es) 2001-12-21 2014-10-01 Human Genome Sciences, Inc. Proteínas de fusión de albúmina e interferón beta
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
TW200500374A (en) 2002-06-28 2005-01-01 Idenlx Cayman Ltd 2' and 3' -nucleoside produrgs for treating flavivridae infections
WO2004002422A2 (en) 2002-06-28 2004-01-08 Idenix (Cayman) Limited 2’-c-methyl-3’-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
CA2506129C (en) 2002-11-15 2015-02-17 Idenix (Cayman) Limited 2'-branched nucleosides and flaviviridae mutation
AU2004224575A1 (en) * 2003-03-28 2004-10-07 Pharmasset Ltd. Compounds for the treatment of flaviviridae infections
WO2004110392A2 (en) * 2003-04-01 2004-12-23 Intermune, Inc. Compositions and methods for treating coronavirus infection and sars
CA2521650A1 (en) * 2003-04-17 2004-10-28 Ares Trading S.A. Interferon beta in severe acute respiratory syndrome (sars)
WO2005003147A2 (en) 2003-05-30 2005-01-13 Pharmasset, Inc. Modified fluorinated nucleoside analogues
EP1641485A4 (en) * 2003-06-09 2009-06-24 Genome Inst Of Singapore INHIBITION OF SARS CORONAVIRUS INFECTION USING ANTIVIRAL DRUGS CLINICALLY TESTED
EP1660116A4 (en) * 2003-08-13 2008-04-30 Smith Howard J & Ass Pty Ltd METHOD FOR THE TREATMENT OF VIRUS INFECTIONS
AR045870A1 (es) * 2003-10-11 2005-11-16 Vertex Pharma Terapia de combinacion para la infeccion de virus de hepatitis c
SI3109244T1 (sl) 2004-09-14 2019-06-28 Gilead Pharmasset Llc Priprava 2'fluoro-2'-alkil-substituiranih ali drugih neobvezno substituiranih ribofuranozil pirimidinov in purinov in njihovih derivatov
MY141025A (en) * 2004-10-29 2010-02-25 Vertex Pharma Dose forms
ES2422556T3 (es) 2006-01-09 2013-09-12 Romark Lab Lc Tratamiento de hepatitis vírica
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
EP2175865A4 (en) 2007-07-25 2012-01-11 Biolex Therapeutics Inc INTERFERON DRUG PRODUCTS WITH CONTROLLED RELEASE AND TREATMENT OF HCV INFECTIONS THEREWITH
TW200946541A (en) 2008-03-27 2009-11-16 Idenix Pharmaceuticals Inc Solid forms of an anti-HIV phosphoindole compound
WO2010075517A2 (en) 2008-12-23 2010-07-01 Pharmasset, Inc. Nucleoside analogs
SG172363A1 (en) 2008-12-23 2011-07-28 Pharmasset Inc Synthesis of purine nucleosides
CL2009002207A1 (es) 2008-12-23 2011-02-18 Gilead Pharmasset Llc Compuestos derivados de 3-hidroxi-5-(9h-purin-9-il)tetrahidrofuran-2-il, inhibidor de la replicacion de arn viral dependiente de arn; composicion farmaceutica; uso para el tratamiento de hepatitis c.
WO2010129947A2 (en) 2009-05-08 2010-11-11 Sciclone Pharmaceuticals, Inc. Alpha thymosin peptides as vaccine enhancers
TWI583692B (zh) 2009-05-20 2017-05-21 基利法瑪席特有限責任公司 核苷磷醯胺
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
AP3515A (en) 2010-03-31 2016-01-11 Gilead Pharmasset Llc Nucleoside phosphoramidates
AU2011311706B2 (en) * 2010-10-05 2015-11-12 Debiopharm S.A. New treatments of Hepatitis C virus infection
JP6069215B2 (ja) 2010-11-30 2017-02-01 ギリアド ファーマセット エルエルシー 化合物
AU2012223528A1 (en) * 2011-03-02 2013-10-24 Joseph M. Fayad Compositions, methods of treatment and diagnostics for treatment of hepatic steatosis alone or in combination with a Hepatitis C virus infection
UA116087C2 (uk) 2011-09-16 2018-02-12 Гіліад Фармассет Елелсі Композиція для лікування вірусу гепатиту c
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
KR20140119012A (ko) 2013-01-31 2014-10-08 길리어드 파마셋 엘엘씨 두 항바이러스 화합물의 병용 제형물
ES2900570T3 (es) 2013-08-27 2022-03-17 Gilead Pharmasset Llc Formulación de combinación de dos compuestos antivirales

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4211771A (en) 1971-06-01 1980-07-08 Robins Ronald K Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US4492537A (en) 1982-12-10 1985-01-08 Awerkamp John B Fluid-operated oil or water well pump
US4917888A (en) 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
JP2514950B2 (ja) 1986-03-10 1996-07-10 エフ・ホフマン―ラ ロシユ アーゲー 化学修飾蛋白質，その製造法および中間体
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
NZ276943A (en) 1993-11-10 1998-02-26 Schering Corp Substituted For Alpha-interferon conjugated to a non-antigenic polymer (preferably a polyalkylene oxide) and its preparation
US5766582A (en) 1994-10-11 1998-06-16 Schering Corporation Stable, aqueous alfa interferon solution formulations
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
JP2758154B2 (ja) 1995-04-06 1998-05-28 エフ・ホフマン−ラ ロシユ アーゲー インターフェロンを含む液体製剤
US6387365B1 (en) * 1995-05-19 2002-05-14 Schering Corporation Combination therapy for chronic hepatitis C infection
EP0858343B1 (en) * 1995-11-02 2004-03-31 Schering Corporation Continuous low-dose cytokine infusion therapy
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
TW517067B (en) 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
WO1999008729A1 (en) 1997-08-13 1999-02-25 Boston Scientific Limited Loading and release of water-insoluble drugs
EP1136075B1 (en) * 1997-09-21 2003-01-15 Schering Corporation Combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection

Also Published As

Publication number Publication date
CZ300540B6 (cs) 2009-06-10
HU230432B1 (hu) 2016-06-28
AU3860099A (en) 1999-12-06
HK1021131A1 (en) 2000-06-02
TWI277424B (en) 2007-04-01
SK17102000A3 (sk) 2001-05-10
IL207259A0 (en) 2010-12-30
NO20005755D0 (no) 2000-11-14
KR100694345B1 (ko) 2007-03-12
EP0956861B1 (en) 2002-04-24
CZ20004177A3 (cs) 2001-04-11
DE69901321T2 (de) 2002-12-12
AU2005220271B2 (en) 2005-11-03
IL139220A (en) 2013-02-28
JP2011173898A (ja) 2011-09-08
NO330715B1 (no) 2011-06-20
AU2005220271A1 (en) 2005-11-03
AU2005220271B8 (en) 2010-11-18
CA2331823A1 (en) 1999-11-25
IL139220A0 (en) 2001-11-25
MY129244A (en) 2007-03-30
ES2172288T3 (es) 2002-09-16
SK288038B6 (en) 2013-01-02
IL207259A (en) 2016-08-31
ATE216591T1 (de) 2002-05-15
EP1213029A1 (en) 2002-06-12
AU2005220271B9 (en) 2010-12-09
CN1309568A (zh) 2001-08-22
JP2002515453A (ja) 2002-05-28
AR019551A1 (es) 2002-02-27
CN1230198C (zh) 2005-12-07
EP2305287A1 (en) 2011-04-06
WO1999059621A1 (en) 1999-11-25
HUP0103423A3 (en) 2003-11-28
JP5281726B2 (ja) 2013-09-04
HUP0103423A2 (hu) 2002-01-28
NO20005755L (no) 2001-01-12
AU766597B2 (en) 2003-10-16
DE69901321D1 (de) 2002-05-29
EP0956861A1 (en) 1999-11-17
KR20010043624A (ko) 2001-05-25
NZ507621A (en) 2002-11-26
BR9910505A (pt) 2001-01-02
PT956861E (pt) 2002-08-30

Similar Documents

Publication Publication Date Title
DK0956861T3 (da) Kombinationsterapi omfattende ribavirin og interferon-alfa til patienter med kronisk hepatitis C infektion, der ikke har modtaget antiviral behandling
NO20031742L (no) HCV-kombinasjonsterapi med ribavirin og pegylert interferon alfa
DK1087778T3 (da) Anvendelse af PEG-IFN-alfa og Ribavirin til behandling af kronisk hepatitis C
NO20015059L (no) HCV-kombinasjonsterapi, inneholdende ribavirin i assosiasjon med antioksydanter
ZA988466B (en) Combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
WO2000037110A3 (en) Ribavirin-pegylated interferon alfa induction hcv combination therapy
NO20001437L (no) Kombinasjonsterapi for Õ utrydde detekterbart HCV-RNA hos pasienter med kronisk hepatitt C-infeksjon
NO974602D0 (no) 1,3-Dihydro-1-(fenylalkyl)-2H-imidazol-2-onderivater med PDE IV- og cytokinaktivitet
WO2000037096A3 (en) Treatment of hepatitis c virus infections with interleukin-10
DK1164996T3 (da) Transdermalt terapeutisk system med nikotin og tilsat monoterpenketoner
ID24910A (id) Karboksilat nukleosid hemisulfat dan penggunaan dalam perlakuan infeksi viral
PE20001386A1 (es) Terapia de combinacion para el vhc por induccion de ribavirina-interferon alfa
WO2000051631A3 (en) Pegylated alpha interferon for hiv therapy
HUP0401659A2 (hu) Eljárás hepatitis-C vírusfertőzés kezelésére eredménytelenül kezelt betegek esetében
AU8353601A (en) Treatment of hepatitis c with thymosin, interferon and ribavirin
DK1311286T3 (da) Behandling af hepatitis C med thymosin og pegyleret interferon
DK0704100T3 (da) Elektronisk styre- og udløserteknik til anbringelse i munden, især til personer med fysisk handicap
NO903601D0 (no) Plasterlignende tilleggsutstyr for anvendelse i forbindelse med sproeyter, saerlig engangssproeyter for blodproevetaking.
PT9467T (pt) Perfil pes de mesa, cadeira e banco
ES1032267Y (es) Faja perfeccionada aplicable en enfermmos operados de colostomia.
TH58469A3 (th) การใช้ Peg-IFN-อัลฟา และไรบาวิริน สำหรับการบำบัดตับอักเสบ C เรื้อรัง
IT1303778B1 (it) Catetere per perfusione tissutale terapeutica.